A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse Events
Number of patients experiencing an adverse event
Overall Study
Yes
Hassan Aladdin, ICTM
Study Director
Genmab
Belgium: Federal Agency for Medicinal Products and Health Products
GEN206
NCT00677924
April 2008
April 2009
Name | Location |
---|